Personalis
PSNL11.8800.83% ( -0.100 )
Personalis (PSNL)
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Perso...
- Open
- 11.820
- High
- 12.040
- Low
- 11.550
- Prev. Close
- 11.980
- Volume
- 2.81M
- Turnover
- 33.14M
- Avg Price
- 11.796
- Bid/Ask Ratio
- --
- Amplitude
- 4.09%
- 52wk High
- 16.390
- Volume Ratio
- 0.42
- Turnover Ratio
- 4.36%
Personalis Analyst Rating
View MoreForecast & Rating
Jul 20, 2026Price forecast
$13.8816.79%
Forecast & RatingBuy
6analysts
- Strong buy66.67%
- Buy0.00%
- Hold33.33%
- Sell0.00%
- Strong sell0.00%
News
- PR Newswire · 22 hours ago
Are FNWD, PSNL, DSGR Obtaining Fair Deals for their Shareholders?
- benzinga_article · Jul 21 at 01:52 PM
Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring
- PR Newswire · Jul 21 at 01:50 PM
Are PSNL, LXP, DSGR, ATAI Obtaining Fair Deals for their Shareholders?
- prnewswire · Jul 21 at 12:55 PM
13:54 ET$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Personalis, Inc. (NASDAQ: PSNL)
- PUBT · Jul 20 at 07:32 AM
Tempus AI agrees to buy Personalis for USD 16.25 per share in USD 1.5 billion deal
- Tip Ranks · Jul 20 at 03:18 PM
Tempus AI (TEM) Drops on $1.7B Personalis Deal; Needham Analyst Calls the Slide a "Market Misread"
